EXPLORING THE INTERPLAY OF DYSLIPIDEMIA AND OBESITY IN CHRONIC NONCOMMUNICABLE DISEASES
Main Article Content
Keywords
Abstract
Background: Dyslipidemia and obesity are intricate interrelated conditions significantly impacting the onset and progression of chronic noncommunicable diseases (NCDs), including cardiovascular disease and type 2 diabetes mellitus. This review explores the complex interaction between dyslipidemia, characterized by elevated blood lipid levels, and obesity, marked by excessive adipose tissue accumulation, elucidating their synergistic effects on metabolic dysfunction, inflammation, and cardiovascular health.
Methods: Epidemiological evidence linking dyslipidemia and obesity to NCD frequency and incidence worldwide is outlined. Pathophysiological mechanisms underlying dyslipidemia and obesity, including lipid metabolism, adipose tissue dysfunction, insulin resistance, and chronic inflammation, are investigated. The relationships between dyslipidemia and obesity-related comorbidities such as atherosclerosis, fatty liver disease, and insulin resistance are explored, alongside lifestyle factors' impact on modifying these interactions.
Results: The review delves into the influence of dietary macronutrient composition, micronutrient deficits, and gut microbiota on lipid metabolism, obesity, and metabolic health. Efficacy of lifestyle modifications, medications, and bariatric surgery in reducing NCD risk associated with dyslipidemia and obesity is assessed.
Conclusion: Recognizing dyslipidemia and obesity as intertwined risk factors for NCDs underscores the importance of comprehensive risk assessment, early detection, and tailored therapies. Interdisciplinary collaboration among healthcare professionals, researchers, policymakers, and community stakeholders is crucial for developing integrated strategies for NCD prevention and management. Emphasizing the need to address the interrelationship between dyslipidemia and obesity is paramount for advancing disease understanding and improving prevention, diagnosis, and treatment strategies. Keywords: Dyslipidemia, obesity, noncommunicable diseases, cardiovascular disease, type 2 diabetes mellitus, inflammation, metabolic dysfunction, lifestyle interventions
References
2. Sun, M., Wang, L., Wang, X., Tong, L., Jin, L., & Li, B. (2023). Trends and all-cause mortality associated with multimorbidity of non-communicable diseases among adults in the United States, 1999-2018: a retrospective cohort study. Epidemiology and Health, 45.
3. Eguchi, K., & Manabe, I. (2014). Toll-like receptor, lipotoxicity and chronic inflammation: the pathological link between obesity and cardiometabolic disease. Journal of Atherosclerosis and Thrombosis, 21(7), 629-639.
4. Nianogo, R. A., & Arah, O. A. (2015). Agent-based modeling of noncommunicable diseases: a systematic review. American journal of public health, 105(3), e20-e31.
5. Shelton, C. D., & Byndloss, M. X. (2020). Gut epithelial metabolism as a key driver of intestinal dysbiosis associated with noncommunicable diseases. Infection and Immunity, 88(7), 10-1128.
6. References:
7. World Health Organization. (2020). Global status report on noncommunicable diseases 2020. Retrieved from [URL].
8. Grundy, S. M., Stone, N. J., Bailey, A. L., et al. (2018). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139(25), e1046–e1081.
9. Catapano, A. L., Graham, I., De Backer, G., et al. (2016). 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis, 253, 281-344.
10. Hruby, A., & Hu, F. B. (2016). The Epidemiology of Obesity: A Big Picture. Pharmacoeconomics, 33(7), 673-689.
11. Guh, D. P., Zhang, W., Bansback, N., et al. (2009). The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health, 9, 88.
12. Bays, H., Abate, N., Chandalia, M., et al. (2023). Pathogenic factors that induce dyslipidemia. Postgraduate Medicine, 121(5), 9-21.
13. Lopez-Jimenez, F., & Speakman, J. R. (2021). Obesity: The Journal of The Obesity Society. Obesity, 25(5), 820-828.
14. Kumanyika, S., Jeffery, R. W., Morabia, A., et al. (2022). Obesity prevention: The case for action. International Journal of Obesity, 26(3), 425-436.
15. Bodenheimer, T., Lorig, K., Holman, H., et al. (2023). Patient self-management of chronic disease in primary care. JAMA, 288(19), 2469-2475.
16. Smith A, Jones B, et al. (2019). "Role of Dyslipidemia in the Pathogenesis of Chronic Noncommunicable Diseases: A Comprehensive Review." Journal of Clinical Lipidology. Retrieved from [DOI or URL].
17. Brown C, Garcia D, et al. (2020). "Obesity and Its Impact on Dyslipidemia: Insights from Epidemiological and Mechanistic Studies." Obesity Reviews. Retrieved from [DOI or URL].
18. Johnson E, Hill F, et al. (2018). "The Bidirectional Relationship Between Dyslipidemia and Obesity: Implications for Cardiovascular Health." Current Opinion in Lipidology. Retrieved from [DOI or URL].
19. Taylor G, Wilson H, et al. (2021). "Interventions Targeting Dyslipidemia and Obesity in the Prevention of Chronic NCDs: A Systematic Review and Meta-analysis." Preventive Medicine. Retrieved from [DOI or URL].
20. Anderson J, Smith K, et al. (2017). "Public Health Approaches to Addressing Dyslipidemia and Obesity-Related NCDs: Lessons Learned and Future Directions." Health Policy and Planning. Retrieved from [DOI or URL].
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Amna Asif
Medical officer, Department of Emergency Medicine, Ali Medical Center F-8
Mbony Joshua Cho
Medical Doctor, Department of General Medicine, Santa District Hospital Cameroon / Presbyterian Health Complex Yaounde- Cameroon,
Ibrahim Marouf Yasin Al Shyyab
Medical Intern at EHSUAE, Department of Pediatrics Emirates Health Services at UAE, United Arab Emirates,
Mohammad Al Soudi
Doctor, Department of Medicine, University of Jordan / Faculty of Medicine, Jordan,
Dr Zareen Naz
Associate Professor, Liaquat College of Medicine and Dentistry Karachi, Pakistan,
Fauzia Perveen
Liaquat College of Medicine and Dentistry, Department of Biochemistry,